C. Matthew Peterson MDCEO & Chairman of the Board
C. Matthew Peterson MD was elected to the position of CEO/Chairman of the Board in March of 2019, after serving on the Scientific Board. Dr. Peterson has collaborated with Dr. Kopeček and and Dr. Ghandehari in the Department of Biopharmaceutics and Pharmaceutical Chemistry in the development of novel drug delivery systems for the treatment of ovarian cancer and other solid tumors. His expertise in these activities involves the design and testing of appropriate ovarian cancer models. Seeing first-hand the efficacy and minimal toxicity of these agents inblinded controlled preclinical studies has energized his desires to see these agents utilized in human clinical trials.
Matthew is the former John A. Dixon Presidential Professor and Chair of the Department of Obstetrics and Gynecology at the University of Utah (2006-2016). Dr. Peterson completed his undergraduate degree from Brigham Young University and his M.D. from the University of Utah. His residency training in obstetrics and gynecology was accomplished at Maricopa Medical Center in Phoenix, Arizona. He completed fellowship training in reproductive endocrinology at University of Miami in Miami, Florida where he began his research on novel therapeutic interventions for ovarian cancer. Throughout his career he has evaluated and utilized various animal models to study the effects of novel polymerically carried drugs in the treatment of ovarian and endometrial cancers.
He also brings to TheraTarget his preclinical drug testing credentials, as well as extensive consultative work on research and development teams in the design, testing and FDA approval of medical devices at Clinical Innovations. His clinical work, as a principal investigator in twenty clinical studies with the NIH and industry, have been particularly noteworthy for highly successful, multicenter recruitment, enrollment, protocol adherence and study completion rates. These studies have included investigational new drug (IND) phase 1, 2 and 3, as well as randomized clinical trials. As CEO, he has helped to focus TheraTarget’s efforts on our unique lead compounds’ immuno-oncologic advantages as well as their advancement into clinical trials.
CEO & Chairman of the Board
CFO & VP Business Development, Board Secretary
Jindřich Henry Kopeček, Ph.D., D.Sc., Founder, Chief Scientific Officer and Inventor, Board MemberHenry Kopeček is Distinguished Professor of Biomedical Engineering and Distinguished Professor of Pharmaceutical Chemistry at the University of Utah. He is an elected member of the US National Academy of Engineering (2011), and elected fellow of the US National Academy of Inventors (2018). He is Honorary Professor of the Sichuan University, China and received a honorary doctorate from the University of Helsinki, Finland. Kopeček’s research interests are focused on biorecognition of macromolecules, bioconjugate chemistry, drug delivery systems, and self-assembled biomaterials. Hydrogels from his laboratory have been in clinical use and polymer-anticancer drug conjugates in clinical trials. Kopeček’s Hirsch index is 100; his publications have been cited 34,546 times (Google Scholar 04/26/2021).Dr. Kopeček’s has an established and impressive record of overall research productivity. He has been working on the design, synthesis, and characterization of hydrogels for clinical applications and his synthetic work resulted in the first publication on stimuli-sensitive hydrogels, with this work ultimately resulting in clinical applications of hydrogels for plastic surgery.His laboratory developed the area of soluble polymeric drug delivery systems. Together with his coworkers, he formulated and implemented a comprehensive approach to the problems of designing macromolecular conjugates to modulate the pharmacokinetics and tissue localization of therapeutic agents. He has made significant contributions to the science of controlled release including: 1) the development of polymers and copolymers of N-(2-hydroxypropyl) methacrylamide (HPMA) as drug carriers, 2) the introduction of enzymatically degradable derivatives of these polymers, 3) fundamental studies of the rates of enzymatic degradation of oligopeptide side-chains in polymers, 4)determination of the relationship between polymer structure and rates of endocytic uptake of those polymers into cells, 5) design and preparation of polymers capable of specific intralysosomal release of chemically bound therapeutic agents, and 6)fundamental studies of tissue localization of polymeric carriers bearing ligands for receptors expressed on the surfaces of specific target cells. HPMA copolymer-drug conjugates have been evaluated in clinical trials.When polymer-drug conjugates faced the hurdle of incongruity between animal and human data on the treatment of solid tumors, Prof. Kopeček and his coworkers rose to meet the challenge, undertaking intensive research efforts to address the major factors for translation into clinical application. They designed backbone degradable HPMA copolymer carriers that possess long intravascular half-life and, consequently, enhanced efficacy in tumor treatment. Furthermore, these new conjugates combined with multivalent HPMA copolymer peptide anti-PD-L1 antagonists (MPPAs) established the polymer-facilitated tumor targeting of immunogenic drugs and surface crosslinking of PD-L1 receptors as a potential new therapeutic strategy to propagate a long-term antitumor immunity, which will broaden the application of immunotherapy to immunosuppressive cancers.Kopeček’s laboratory also designed a new paradigm of nanomedicines, called drug-free macromolecular therapeutics. Using polymer carriers bearing multiple ligands for crosslinking and clustering receptors expressed on the surface of specific target cells apoptosis is induced without the participation of low molecular weight drugs.
Co-Founder, Chief Scientific Officer
Chief of Manufacturing, Quality and Regulatory Affairs
2500 S. State St.
Salt Lake City, UT